Results · Apr-Jun 2026
Lasa Supergenerics Q1 FY27 results
Sales fell 94% to ₹1.2 crore from ₹20 crore in Apr-Jun 2025.
Operating profit was −₹1.4 crore, an operating margin of −113.4% (down 110.9 points from a year ago).
The net loss narrowed to ₹3.6 crore from ₹21.1 crore.
Against Jan-Mar 2026: loss narrows.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 1.2 | 20.0 | −94% |
| Operating profit (EBITDA) | -1.4 | -0.5 | n/m |
| Operating margin | −113.4% | −2.5% | −110.9 pts |
| Net profit | -3.6 | -21.1 | loss narrows |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.